A2001 • 2026

Establishes pharmacist licensing exemption for certain dialysis-related drugs and devices.

Passed Legislature

This bill passed both chambers and reached final enrollment, even if later executive action is not shown here.

Sponsor: Quijano, Annette
Last action: 2026-06-18
Official status: Reported out of Assembly Committee, 2nd Reading
Effective date: Not listed

Plain English Breakdown

Using official source text because the generated explanation was unavailable or could not be confirmed against the official bill text.

Establishes pharmacist licensing exemption for certain dialysis-related drugs and devices.

What This Bill Does

Establishes pharmacist licensing exemption for certain dialysis-related drugs and devices.
Topic: 2nd Reading in the Assembly Fiscal note: This bill has not been certified by OLS for a fiscal note.

Limits and Unknowns

This entry is temporarily using official source text because the generated explanation could not be confirmed against the official bill text during the last sync.

Bill History

2026-06-18 New Jersey Legislature
Transferred to Assembly Health Committee
2026-06-18 New Jersey Legislature
Reported out of Assembly Committee, 2nd Reading
2026-02-12 New Jersey Legislature
Reported and Referred to Assembly Oversight, Reform and Federal Relations Committee
2026-01-13 New Jersey Legislature
Introduced, Referred to Assembly Regulated Professions Committee

Official Summary Text

Establishes pharmacist licensing exemption for certain dialysis-related drugs and devices.
Topic:
2nd Reading in the Assembly
Fiscal note:
This bill has not been certified by OLS for a fiscal note.

Current Bill Text

Read the full stored bill text

A2001 AHE Statement 6/18/26

ASSEMBLY HEALTH COMMITTEE

STATEMENT TO

ASSEMBLY,
No. 2001

STATE
OF NEW JERSEY

DATED:
�JUNE
18, 2026

����� The Assembly Health Committee reports favorably
Assembly Bill No. 2001.

�����
This
bill exempts drug manufacturers and wholesale drug distributors from the
requirement of being a licensed pharmacist when they are engaged in the
distribution of dialysate drugs or devices to patients with end-stage renal
disease under certain circumstances.

���� Under
the bill, drug manufacturers and wholesale drug distributors would not be
subject to pharmacist licensing requirements to the extent that they are
engaged in the distribution of dialysate drugs or devices necessary to perform
home dialysis on patients with end-stage renal disease. For the purposes of the
bill, the following would be required of the drugs and devices:

���� (1) �approval
by the United States Food and Drug Administration;

���� (2) �be
held by an entity that is properly registered;

���� (3) �be
held and delivered in original, sealed, and labeled packaging;

���� (4) �delivery
only by the manufacturer or the manufacturer�s agent and only upon receipt of a
physician�s order;

���� (5) �delivery
is made to a patient, the patient�s designee, a health care provider, or an
institution for administration or delivery of the dialysis therapy to the
patient; and

���� (6) �periodic
oversight of manufacturers and distributors by a licensed pharmacist.